ArticleCureus2026
Comparative Analysis of Effectiveness of Dolutegravir-Based Regimen (TLD) vs. Efavirenz-Based Regimen (TLE) to Prevent Mother-to-Child Transmission of HIV.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe National AIDS Control Organisation (NACO) in India now recommends a dolutegravir-based regimen (TLD) for pregnant women to prevent mother-to-child transmission (MTCT) of HIV. However, evidence comparing its effectiveness with the previously used Efavirenz-based regimen (TLE) in reducing MTCT remains limited.
aimTo compare the effectiveness of the TLD and TLE regimens in preventing mother-to-child transmission of HIV. METHODOLOGY: HIV-positive pregnant women initiated on the TLD regimen were categorized as group A, while those receiving the TLE regimen formed group B. All newborns received nevirapine prophylaxis and underwent HIV testing at 6 weeks, 6 months, 12 months, and 18 months of age.
resultAmong the 67 women in group A, no infants tested positive for HIV. In group B, two infants were HIV-positive (MTCT rate 4.6%). The difference in transmission rates showed no statistical significance (χ²= 2.816; p=0.09), but the DTG-based (TLD) regimen showed a trend toward lower MTCT compared to the EFV-based (TLE) regimen. At initiation, the mean CD4 count in the TLD group was 444.5±199.79 cells/mm with a slight decline after 6 months of therapy (CD4 count= 405.09±147.52). The mean birth weight was 2.75±0.39 kg in group A and 2.59±0.46 in group B.
conclusionThe TLD regimen was associated with a trend towards lower MTCT of HIV compared to the TLE regimen. Thus, continued use of dolutegravir-based therapy is recommended to support national and global goals of eliminating new HIV infections among exposed infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.